Global_Prevalence_of_Celiac_Disease_in_Patients_With_Rome_III_and.pdf
1.6 MB
Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.
AJG December 2025
flgastro-2025-103183.full.pdf
1.2 MB
Nutrition in MASLD: a patient focused, evidence-based clinician’s guide.
BMJ, November 2025
jessica-r-biesiekierski-non-coeliac-gluten-sensitivity.pdf
547.9 KB
Non-coeliac gluten sensitivity
The Lancet,, November 2025
✳️ Interpretation of Hepatitis B serological markers and the new advanced markers
Hepatitis B virus (HBV) infection is diagnosed and characterized through a panel of serological markers, each providing specific information about infection status, disease phase, and immunity. Understanding these markers is essential for proper diagnosis, management, and treatment decisions.
✳️Core Serological Markers
▫️HBsAg (Hepatitis B surface antigen): Indicates active HBV infection, either acute or chronic. Persistence beyond 6 months defines chronic infection. HBsAg can be translated from both covalently closed circular DNA (cccDNA) and integrated HBV DNA in the host genome.
▫️Anti-HBs (Antibody to HBsAg): Protective antibody indicating recovery from infection or successful vaccination. Levels ≥10 mIU/mL at 1-2 months after completing vaccination indicate immunity. Among vaccine responders, anti-HBs can decline below 10 mIU/mL over time, but most remain immune and mount an anamnestic response upon re-exposure.
▫️Anti-HBc (Antibody to core antigen): Develops in all HBV infections and typically persists for life. Total anti-HBc detects both IgM and IgG antibodies. Persons immune through vaccination do not develop anti-HBc.
▫️Anti-HBc IgM: Indicates acute infection or acute exacerbation of chronic hepatitis B. During chronic infection, IgM anti-HBc typically disappears while total anti-HBc persists.
▫️HBeAg (Hepatitis B e antigen): Marker of high viral replication and infectivity. Its presence correlates with elevated HBV DNA levels.
Anti-HBe (Antibody to HBeAg): Appears after HBeAg clearance, indicating lower viral replication. Loss of HBeAg with appearance of anti-HBe is a favorable marker during acute infection.
▫️HBV DNA: Primary marker of viral replication measured by quantitative real-time PCR. Results should be expressed in IU/mL using standardized assays. HBV DNA levels guide treatment decisions and monitor therapeutic response.
✳️ Common Serological Patterns
▫️Acute infection: HBsAg positive, anti-HBc IgM positive, anti-HBs negative.
▫️Chronic infection: HBsAg positive, anti-HBc (total) positive, anti-HBs negative, anti-HBc IgM negative.
▫️Resolved infection: HBsAg negative, anti-HBc positive, anti-HBs positive.
▫️Immune due to vaccination: HBsAg negative, anti-HBc negative, anti-HBs positive.
▫️Susceptible (never infected): All markers negative.
✳️ Isolated Anti-HBc Pattern
The isolated anti-HBc pattern (anti-HBc positive, HBsAg negative, anti-HBs negative) has several potential interpretations.
Resolved infection with waning anti-HBs (most common): Previous HBV infection where anti-HBs has declined to undetectable levels. Studies show this pattern can fluctuate, with anti-HBs becoming intermittently detectable, supporting resolved infection rather than occult viremia.
Occult HBV infection: Low-level viremia with HBV DNA detectable by PCR, often due to mutant HBsAg not detected by standard assays. This occurs less commonly than waning immunity.
Window period of acute infection: Transient phase where HBsAg has cleared but anti-HBs has not yet appeared. This pattern evolves over time.
False positive: Particularly in low-prevalence populations or with older, less specific assays.
For isolated anti-HBc in intermediate- to high-risk populations, the most common explanation is previous HBV exposure with waning anti-HBs. HBV DNA testing should be considered in immunocompromised patients to exclude occult infection.
✳️ Advanced Biomarkers
Quantitative HBsAg (qHBsAg): Reflects cccDNA transcriptional activity and integrated HBV DNA. Levels are higher in HBeAg-positive than HBeAg-negative patients. In HBeAg-positive patients, lower HBsAg levels correlate with higher rates of significant fibrosis and cirrhosis. qHBsAg <1,000 IU/mL combined with HBV DNA ≤2,000 IU/mL suggests inactive chronic hepatitis B, while qHBsAg <1,000 IU/mL predicts spontaneous HBsAg clearance in HBeAg-negative patients with low viral load.
HBV core-related antigen (HBcrAg): Composite marker comprising HBcAg, HBeAg, and p22cr precursor protein.
Hepatitis B virus (HBV) infection is diagnosed and characterized through a panel of serological markers, each providing specific information about infection status, disease phase, and immunity. Understanding these markers is essential for proper diagnosis, management, and treatment decisions.
✳️Core Serological Markers
▫️HBsAg (Hepatitis B surface antigen): Indicates active HBV infection, either acute or chronic. Persistence beyond 6 months defines chronic infection. HBsAg can be translated from both covalently closed circular DNA (cccDNA) and integrated HBV DNA in the host genome.
▫️Anti-HBs (Antibody to HBsAg): Protective antibody indicating recovery from infection or successful vaccination. Levels ≥10 mIU/mL at 1-2 months after completing vaccination indicate immunity. Among vaccine responders, anti-HBs can decline below 10 mIU/mL over time, but most remain immune and mount an anamnestic response upon re-exposure.
▫️Anti-HBc (Antibody to core antigen): Develops in all HBV infections and typically persists for life. Total anti-HBc detects both IgM and IgG antibodies. Persons immune through vaccination do not develop anti-HBc.
▫️Anti-HBc IgM: Indicates acute infection or acute exacerbation of chronic hepatitis B. During chronic infection, IgM anti-HBc typically disappears while total anti-HBc persists.
▫️HBeAg (Hepatitis B e antigen): Marker of high viral replication and infectivity. Its presence correlates with elevated HBV DNA levels.
Anti-HBe (Antibody to HBeAg): Appears after HBeAg clearance, indicating lower viral replication. Loss of HBeAg with appearance of anti-HBe is a favorable marker during acute infection.
▫️HBV DNA: Primary marker of viral replication measured by quantitative real-time PCR. Results should be expressed in IU/mL using standardized assays. HBV DNA levels guide treatment decisions and monitor therapeutic response.
✳️ Common Serological Patterns
▫️Acute infection: HBsAg positive, anti-HBc IgM positive, anti-HBs negative.
▫️Chronic infection: HBsAg positive, anti-HBc (total) positive, anti-HBs negative, anti-HBc IgM negative.
▫️Resolved infection: HBsAg negative, anti-HBc positive, anti-HBs positive.
▫️Immune due to vaccination: HBsAg negative, anti-HBc negative, anti-HBs positive.
▫️Susceptible (never infected): All markers negative.
✳️ Isolated Anti-HBc Pattern
The isolated anti-HBc pattern (anti-HBc positive, HBsAg negative, anti-HBs negative) has several potential interpretations.
Resolved infection with waning anti-HBs (most common): Previous HBV infection where anti-HBs has declined to undetectable levels. Studies show this pattern can fluctuate, with anti-HBs becoming intermittently detectable, supporting resolved infection rather than occult viremia.
Occult HBV infection: Low-level viremia with HBV DNA detectable by PCR, often due to mutant HBsAg not detected by standard assays. This occurs less commonly than waning immunity.
Window period of acute infection: Transient phase where HBsAg has cleared but anti-HBs has not yet appeared. This pattern evolves over time.
False positive: Particularly in low-prevalence populations or with older, less specific assays.
For isolated anti-HBc in intermediate- to high-risk populations, the most common explanation is previous HBV exposure with waning anti-HBs. HBV DNA testing should be considered in immunocompromised patients to exclude occult infection.
✳️ Advanced Biomarkers
Quantitative HBsAg (qHBsAg): Reflects cccDNA transcriptional activity and integrated HBV DNA. Levels are higher in HBeAg-positive than HBeAg-negative patients. In HBeAg-positive patients, lower HBsAg levels correlate with higher rates of significant fibrosis and cirrhosis. qHBsAg <1,000 IU/mL combined with HBV DNA ≤2,000 IU/mL suggests inactive chronic hepatitis B, while qHBsAg <1,000 IU/mL predicts spontaneous HBsAg clearance in HBeAg-negative patients with low viral load.
HBV core-related antigen (HBcrAg): Composite marker comprising HBcAg, HBeAg, and p22cr precursor protein.
❤3
May reflect intrahepatic cccDNA levels, particularly in HBeAg-positive patients, and help define disease phase and predict treatment response. Total anti-HBc levels correlate with disease activity and decline with successful antiviral therapy.
HBV RNA: Marker of cccDNA transcriptional activity. Correlates with HBeAg loss during treatment and may predict viral rebound after nucleos(t)ide analog discontinuation.
✳️ Clinical Assessment
Initial evaluation of HBsAg-positive patients should include a comprehensive history focusing on risk factors, family history of HBV and hepatocellular carcinoma, and alcohol use.
Laboratory assessment should include complete blood count with platelets, liver function tests (AST, ALT, bilirubin, alkaline phosphatase, albumin), coagulation studies (PT/INR), HBeAg/anti-HBe, quantitative HBV DNA, and testing for coinfections (anti-HAV, anti-HCV, anti-HDV, anti-HIV in at-risk individuals).
Imaging with abdominal ultrasound and assessment of fibrosis stage using transient elastography or serum fibrosis panels (APRI, FIB-4) should be performed. Liver biopsy may be indicated when treatment decisions are unclear or to assess for other causes of liver disease.
HBV genotype determination can inform prognosis and treatment response, particularly for interferon-based therapy. Genotype A shows higher rates of HBeAg and HBsAg loss with interferon compared to genotypes B-D.
HBV RNA: Marker of cccDNA transcriptional activity. Correlates with HBeAg loss during treatment and may predict viral rebound after nucleos(t)ide analog discontinuation.
✳️ Clinical Assessment
Initial evaluation of HBsAg-positive patients should include a comprehensive history focusing on risk factors, family history of HBV and hepatocellular carcinoma, and alcohol use.
Laboratory assessment should include complete blood count with platelets, liver function tests (AST, ALT, bilirubin, alkaline phosphatase, albumin), coagulation studies (PT/INR), HBeAg/anti-HBe, quantitative HBV DNA, and testing for coinfections (anti-HAV, anti-HCV, anti-HDV, anti-HIV in at-risk individuals).
Imaging with abdominal ultrasound and assessment of fibrosis stage using transient elastography or serum fibrosis panels (APRI, FIB-4) should be performed. Liver biopsy may be indicated when treatment decisions are unclear or to assess for other causes of liver disease.
HBV genotype determination can inform prognosis and treatment response, particularly for interferon-based therapy. Genotype A shows higher rates of HBeAg and HBsAg loss with interferon compared to genotypes B-D.
❤1
Indications for ERCP During Pregnancy (Adapted From American Society for Gastrointestinal Endoscopy Guidelines )
Zenker diverticulum (ZD) is a false diverticulum (herniation of mucosa and submucosa only) that typically herniates through the Killian triangle at the dorsal hypopharynx. The best confirmatory test in patients with ZD is barium esophagram with dynamic continuous fluoroscopy. The characteristic outpouching in the posterior pharyngoesophageal wall confirms the diagnosis.
Patients presenting with symptomatic ZD should undergo open surgical or endoscopic treatment.
Patients presenting with symptomatic ZD should undergo open surgical or endoscopic treatment.
quantifying_patient_preferences_for_risk_tolerance.23.pdf
1.1 MB
Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease
bmj-2025-079050.full.pdf
884.9 KB
State of the art review : Medical management of inflammatory bowel diseases.
BMJ 19,December 2025
❤5